Connaughton Bernadette (CIK 1662521) reported 13 SEC Form 4 insider transactions across 1 companies over the past 18 months (most recent 2026-07-02). Recent activity: Sell HALO (1,000 shares), Sell HALO (625 shares), Sell HALO (1,625 shares), Buy HALO (6,796 shares), Sell HALO (2,000 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-02 | HALOZYME THERAPEUTICS, INC. (HALO) | Director | Sell | 1,000 | $76,395 |
| 2026-07-02 | HALOZYME THERAPEUTICS, INC. (HALO) | Director | Sell | 625 | $48,256 |
| 2026-06-02 | HALOZYME THERAPEUTICS, INC. (HALO) | Director | Sell | 1,625 | $107,591 |
| 2026-05-07 | HALOZYME THERAPEUTICS, INC. (HALO) | Director | Buy | 6,796 | $0 |
| 2026-01-06 | HALOZYME THERAPEUTICS, INC. (HALO) | Director | Sell | 2,000 | $140,500 |
| 2025-12-01 | HALOZYME THERAPEUTICS, INC. (HALO) | Director | Sell | 829 | $59,356 |
| 2025-11-12 | HALOZYME THERAPEUTICS, INC. (HALO) | Director | Sell | 2,000 | $136,960 |
| 2025-10-01 | HALOZYME THERAPEUTICS, INC. (HALO) | Director | Sell | 1,500 | $112,635 |
| 2025-10-01 | HALOZYME THERAPEUTICS, INC. (HALO) | Director | Sell | 500 | $37,850 |
| 2025-09-02 | HALOZYME THERAPEUTICS, INC. (HALO) | Director | Sell | 100 | $7,171 |
| 2025-09-02 | HALOZYME THERAPEUTICS, INC. (HALO) | Director | Sell | 2,977 | $219,167 |
| 2025-09-02 | HALOZYME THERAPEUTICS, INC. (HALO) | Director | Sell | 923 | $68,404 |
| 2025-05-02 | HALOZYME THERAPEUTICS, INC. (HALO) | Director | Buy | 4,165 | $0 |
Source: SEC Form 4 filings · as of 2026-07-02